| A new class of angiotensin-converting enzyme inhibitors AA Patchett, E Harris, EW Tristram, MJ Wyvratt, MT Wu, D Taub, ... Nature 288 (5788), 280-283, 1980 | 978 | 1980 |
| SCH-C (SCH 351125), an orally bioavailable, small molecule antagonist of the chemokine receptor CCR5, is a potent inhibitor of HIV-1 infection in vitro and in vivo JM Strizki, S Xu, NE Wagner, L Wojcik, J Liu, Y Hou, M Endres, A Palani, ... Proceedings of the National Academy of Sciences 98 (22), 12718-12723, 2001 | 447 | 2001 |
| Nonpeptide angiotensin II receptor antagonists: the next generation in antihypertensive therapy RR Wexler, WJ Greenlee, JD Irvin, MR Goldberg, K Prendergast, ... Journal of Medicinal Chemistry 39 (3), 625-656, 1996 | 412 | 1996 |
| Renin inhibitors. WJ Greenlee Medicinal research reviews 10 (2), 173-236, 1990 | 365 | 1990 |
| Discovery of a novel, orally active himbacine-based thrombin receptor antagonist (SCH 530348) with potent antiplatelet activity S Chackalamannil, Y Wang, WJ Greenlee, Z Hu, Y Xia, HS Ahn, ... Journal of medicinal chemistry 51 (11), 3061-3064, 2008 | 336 | 2008 |
| 5-Chloro-3-(phenylsulfonyl) indole-2-carboxamide: a novel, non-nucleoside inhibitor of HIV-1 reverse transcriptase TM Williams, TM Ciccarone, SC MacTough, CS Rooney, SK Balani, ... Journal of medicinal chemistry 36 (9), 1291-1294, 1993 | 311 | 1993 |
| Identification of peptide binding residues in the extracellular domains of the AT1 receptor. SA Hjorth, HT Schambye, WJ Greenlee, TW Schwartz Journal of Biological Chemistry 269 (49), 30953-30959, 1994 | 227 | 1994 |
| Discovery of the 3-imino-1, 2, 4-thiadiazinane 1, 1-dioxide derivative verubecestat (MK-8931)–a β-site amyloid precursor protein cleaving enzyme 1 inhibitor for the treatment … JD Scott, SW Li, APJ Brunskill, X Chen, K Cox, JN Cumming, M Forman, ... Journal of medicinal chemistry 59 (23), 10435-10450, 2016 | 175 | 2016 |
| Discovery of cyclic acylguanidines as highly potent and selective β-site amyloid cleaving enzyme (BACE) inhibitors: Part I Inhibitor design and validation Z Zhu, ZY Sun, Y Ye, J Voigt, C Strickland, EM Smith, J Cumming, L Wang, ... Journal of medicinal chemistry 53 (3), 951-965, 2010 | 173 | 2010 |
| Potent, selective, and orally active adenosine A2A receptor antagonists: arylpiperazine derivatives of pyrazolo [4, 3-e]-1, 2, 4-triazolo [1, 5-c] pyrimidines BR Neustadt, J Hao, N Lindo, WJ Greenlee, AW Stamford, D Tulshian, ... Bioorganic & Medicinal Chemistry Letters 17 (5), 1376-1380, 2007 | 170 | 2007 |
| Substituted imidazo-fused 6-membered heterocycles as angiotensin II antagonists PK Chakravarty, WJ Greenlee, NB Mantlo, AA Patchett, TF Walsh US Patent 5,332,744, 1994 | 167 | 1994 |
| Application of fragment-based NMR screening, X-ray crystallography, structure-based design, and focused chemical library design to identify novel μM leads for the development … YS Wang, C Strickland, JH Voigt, ME Kennedy, BM Beyer, MM Senior, ... Journal of medicinal chemistry 53 (3), 942-950, 2010 | 162 | 2010 |
| Total synthesis of cytochalasin B G Stork, Y Nakahara, Y Nakahara, WJ Greenlee Journal of the American Chemical Society 100 (24), 7775-7777, 1978 | 161 | 1978 |
| Discovery of potent orally active thrombin receptor (protease activated receptor 1) antagonists as novel antithrombotic agents S Chackalamannil, Y Xia, WJ Greenlee, M Clasby, D Doller, H Tsai, ... Journal of medicinal chemistry 48 (19), 5884-5887, 2005 | 157 | 2005 |
| Structure based design of iminohydantoin BACE1 inhibitors: identification of an orally available, centrally active BACE1 inhibitor JN Cumming, EM Smith, L Wang, J Misiaszek, J Durkin, J Pan, U Iserloh, ... Bioorganic & medicinal chemistry letters 22 (7), 2444-2449, 2012 | 156 | 2012 |
| Discovery of 4-[(Z)-(4-Bromophenyl)- (ethoxyimino)methyl]-1‘-[(2,4-dimethyl-3- pyridinyl)carbonyl]-4‘-methyl-1,4‘- bipiperidine N-Oxide (SCH 351125): An Orally … A Palani, S Shapiro, JW Clader, WJ Greenlee, K Cox, J Strizki, M Endres, ... Journal of medicinal chemistry 44 (21), 3339-3342, 2001 | 152 | 2001 |
| In vitro pharmacology of L-158,809, a new highly potent and selective angiotensin II receptor antagonist. RS Chang, PK Siegl, BV Clineschmidt, NB Mantlo, PK Chakravarty, ... The Journal of pharmacology and experimental therapeutics 262 (1), 133-138, 1992 | 141 | 1992 |
| A potent, orally active, balanced affinity angiotensin II AT1 antagonist and AT2 binding inhibitor SE de Laszlo, CS Quagliato, WJ Greenlee, AA Patchett, RSL Chang, ... Journal of medicinal chemistry 36 (21), 3207-3210, 1993 | 139 | 1993 |
| Heterocyclic aspartyl protease inhibitors Z Zhu, BA McKittrick, ZY Sun, CY Yuanzan, JH Voigt, C Strickland, ... US Patent 7,700,603, 2010 | 135 | 2010 |
| Design of a selective insulin receptor tyrosine kinase inhibitor and its effect on glucose uptake and metabolism in intact cells R Saperstein, PP Vicario, HV Strout, E Brady, EE Slater, WJ Greenlee, ... Biochemistry 28 (13), 5694-5701, 1989 | 133 | 1989 |
